norfluoxetine has been researched along with Coxsackie Virus Infections in 1 studies
norfluoxetine: metabolite of fluoxetine; RN given refers to parent cpd without isomeric designation
| Excerpt | Relevance | Reference |
|---|---|---|
| " Median effective dose was interpolated from the triplicated experiments and the dose-response curves were generated for each drug-virus combination." | 1.56 | A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses. ( Honkimaa, A; Hyöty, H; Sioofy-Khojine, AB, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sioofy-Khojine, AB | 1 |
| Honkimaa, A | 1 |
| Hyöty, H | 1 |
1 other study available for norfluoxetine and Coxsackie Virus Infections
| Article | Year |
|---|---|
A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses.
Topics: A549 Cells; Amides; Antiviral Agents; Azithromycin; Benzimidazoles; Coxsackievirus Infections; Diabe | 2020 |